TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05318521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen modified release tablet 800 mg
Description: Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
Study: NCT05929534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active intermittent Theta Burst Stimulation
Description: Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham intermittent Theta Burst Stimulation
Description: Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
Study: NCT05425771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti Reflux Mucosa Ablation
Description: Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
Study: NCT05595525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064NM pico Laser
Description: There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064NM pico Laser
Description: There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755NM pico Laser
Description: There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755NM pico Laser
Description: There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
Study: NCT05777928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OverStitch™ Endoscopic Suturing System
Description: Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
Study: NCT04836286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotive Intelligent Spaces (EIS)
Description: The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
Study: NCT05816681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1230
Description: Daewoong Pharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWB2001
Description: Daewoong Bio
Study: NCT05669521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK-112690
Description: TK112690 treatment Post 5-FU chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment Post 5-FU chemotherapy
Study: NCT05994625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stream™ Platform
Description: Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stream™ Platform with Risk Score Omitted
Description: Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform.
Study: NCT05800990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Research participants will be assigned to two dietary conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Research participants will be assigned to two dietary conditions.
Study: NCT05858320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SmartHF application
Description: Adaptive medication recommendations that can be shared with the participants HF provider.
Study: NCT06157424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
Study: NCT05858320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmartHF application
Description: Adaptive medication recommendations that can be shared with the participants HF provider.
Study: NCT05609227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: The application, compatible with IOS and android systems for patients candidate for stem cell transplantation, could be applied whenever needed information relating to transplantation process.
Study: NCT05837754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C8-C12
Description: 5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
Study: NCT05997589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend financial health educational program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05911568

Intervention type: PROCEDURE
Intervention: Endovascular Stroke Treatment
Description: Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke

Intervention type: OTHER
Intervention: Medical Management
Description: Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.
Study: NCT05837754

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
Study: NCT06093802

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug-induced Sleep Endoscopy findings (identified obstruction sites)
Description: As described above

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Drug-induced Sleep Endoscopy findings (identified obstruction sites)
Description: As described above
Study: NCT05996926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Transvaginal Ultrasound (3D TVS)
Description: In this study, Three-Dimensional Transvaginal Ultrasound will be employed as one of the interventions to evaluate Cesarean Scar Defects (CSD) and associated complications in symptomatic patients with a history of cesarean section.~Procedure: A specialized ultrasound machine (Samsung WS80A) equipped with a transvaginal 2-11 MHz probe will be used for the Three-Dimensional Transvaginal Ultrasound examination. The examination will be conducted in the 1st half of the menstrual cycle. The ultrasound probe will be introduced into the posterior fornix of the vagina to capture three-dimensional images of the uterus and scar area. The examiner will identify and measure the characteristics of the Cesarean Scar Defects (CSD), including length, depth, width, volume, residual myometrial thickness, adjacent myometrial thickness, and presence of any branches.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saline-Infused Sonography (Sonohystrography)
Description: The Sonohystrography will be performed using a Toshiba ECCO CEE SSA-340A ultrasound equipment with a 7.5 MHz transvaginal probe. A sterile vaginal speculum will be inserted, the cervix cleansed with an antiseptic solution, and a thin Foley's catheter inserted into the cervical os. Sterile saline solution will be infused into the uterus through the catheter to distend the uterine cavity. The examiner will use the ultrasound probe to visualize and assess the uterine cavity, focusing on identifying and measuring Cesarean Scar Defects (CSD) characteristics, including depth, width, volume, and myometrial thickness.
Study: NCT05369390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 A
Description: Participants will receive NNC0487-0111 A tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 A
Description: Participants will receive NNC0487-0111 A tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 A
Description: Participants will receive NNC0487-0111 A tablet once daily.
Study: NCT05505422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine ECMO
Description: Routine ECMO during lung tansplant
Study: NCT05369390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 B
Description: Participants will receive NNC0487-0111 B tablet once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo B (NNC0487-0111 B)
Description: Participants will receive placebo matched to NNC0487-0111 B tablet once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0487-0111 A)
Description: Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
Study: NCT05505422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On demand ECMO
Description: Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation \> 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field
Study: NCT05705726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided facia iliaca block
Description: Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous drug
Description: Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
Study: NCT05369390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0487-0111 A)
Description: Participants will receive placebo matched to NNC0487-0111 A tablet once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0487-0111 A)
Description: Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
Study: NCT05445193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEaters Choice Module
Description: There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
Study: NCT05440825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRelax
Description: Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation exercises
Description: Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
Study: NCT04697225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss strategies
Description: Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss coaching sessions and email support
Description: Participants will receive weekly coaching sessions and tailored support emails.
Study: NCT06137352

Intervention type: OTHER
Intervention: Follow up
Description: Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
Study: NCT05531240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Prostate Resection (TURP)
Description: Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
Study: NCT06419166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.~Other Name: CD19-BCMA CAR-T cells
Study: NCT05496010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling and Ischemic Compression Technique
Description: For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling and Ischemic Compression Technique
Description: For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups.
Study: NCT04816253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline irrigation and No other drug placed after extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednsolone will be injected half an hour preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone and Hyaluronic acid
Description: Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Study: NCT04891120

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treadmill test (Bruce protocol)
Description: Treadmill test performed with and without a mask.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treadmill test (Bruce protocol)
Description: Treadmill test performed with and without a mask.
Study: NCT05087745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT05641961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship mobile application
Description: Mobile phone application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
Study: NCT05223101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminone 80 mg
Description: Single administration of telmisartan 80 mg
Study: NCT04029844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colibri TAVI System
Description: Implantation of Colibri heart valve
Study: NCT06521450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anti incontinence surgery
Description: anti incontinence surgery with prolapse surgery will be performed simultaneously

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anti incontinence surgery
Description: anti incontinence surgery with prolapse surgery will be performed simultaneously
Study: NCT05194566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS
Description: Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
Study: NCT04772742

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab - 100 mg, solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eptinezumab
Description: Eptinezumab - 100 mg, solution for infusion
Study: NCT06054204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lateral bony window
Description: bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
Study: NCT05223101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminone 80 mg
Description: Single administration of telmisartan 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Micardis 80 mg
Description: Single administration of telmisartan 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Micardis 80 mg
Description: Single administration of telmisartan 80 mg
Study: NCT05418712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-150 for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Solution or Suspension for oral administration.